Clinical Trial Update: Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravitreal DE-122 plus Lucentis versus Lucentis alone for wet age-related macular degeneration completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• DE-122
• Lucentis (ranibizumab)

Snippet

Sponsor: Santen Inc. | Conditions: Age-Related Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2021-07-13